Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa

AIDS

Volumn 27, Issue 17, 2013, Pages 2775-2786

  Amornkul, Pauli N ^a   Karita, Etienne ^b   Kamali, Anatoli ^c   Rida, Wasima N ^d   Sanders, Eduard J ^e,f   Lakhi, Shabir ^g   Price, Matt A ^a   Kilembe, William ^g   Cormier, Emmanuel ^a   Anzala, Omu ^h   Latka, Mary H ⁱ   Bekker, Linda Gail ^j   Allen, Susan A ^b,g,k   Gilmour, Jill ^l   Fast, Patricia E ^a  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b Project San Francisco   (Rwanda)

^c Medical Research Council Uganda Virus Research Institute Uganda Research Unit on AIDS   (Uganda)

^d Biostatistics Consultant   (United States)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g Zambia Emory HIV Research Project   (Zambia)

^h UNIVERSITY OF NAIROBI   (Kenya)

ⁱ AURUM INSTITUTE   (South Africa)

^j UNIVERSITY OF CAPE TOWN   (South Africa)

^k EMORY UNIVERSITY   (United States)

^l IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Africa; AIDS; CD4+ cell count; HIV disease progression; HIV 1 subtype; HIV serodiscordant couples; Men who have sex with men; Viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HLA ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ALLELE; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; FEMALE; HAZARD RATIO; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RWANDA; SEROCONVERSION; SOUTH AFRICA; UGANDA; VIRUS LOAD; ZAMBIA;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VIRAL LOAD; YOUNG ADULT;

EID: 84888286545     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000012     Document Type: Article

References (40)

1. Laga M, Piot P. Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behind. AIDS 2012; 26:1223-1229.
2. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13-23.
3. Population Reference Bureau. World Population Data Sheet, 2012: Washington, DC: Population Reference Bureau; 2012.
4. UNAIDS. Global AIDS epidemic facts and figures, 2012: Geneva, Switzerland; UNAIDS; 2012.
5. Hessol NA, Koblin BA, van Griensven GJ, Bacchetti P, Liu JY, Stevens CE, et al. Progression of human immunodeficiency virus type 1 (HIV-1) infection among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1991. Am J Epidemiol 1994; 139: 1077-1087.
6. Veugelers PJ, Strathdee SA, Kaldor JM, Shafer KA, Moss AR, Schechter MT, et al. Associations of age, immunosuppression, and AIDS among homosexual men in the Tricontinental Seroconverter Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:435-441.
7. Prins M, Veugelers PJ. Comparison of progression and nonprogression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. AIDS 1997; 11:621-631.
8. Gao F, Robertson DL, Morrison SG, Hui H, Craig S, Decker J, et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996; 70:7013-7029.
9. Amornkul PN, Tansuphasawadikul S, Limpakarnjanarat K, Likanonsakul S, Young N, Eampokalap B, et al. Clinical disease associated with HIV-1 subtype B0 and E infection among 2104 patients in Thailand. AIDS 1999; 13:1963-1969.
10. Csillag C. HIV-1 subtype C in Brazil. Lancet 1994; 344:1354.
11. Djomand G, Duerr A, Faulhaber JC, Struchiner CJ, Pacheco AG, Barroso PF, et al. Viral load and CD4 count dynamics after HIV-1 seroconversion in homosexual and bisexual men in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2006; 43:401-404.
12. Mehendale SM, Bollinger RC, Kulkarni SS, Stallings RY, Brookmeyer RS, Kulkarni SV, et al. Rapid disease progression in human immunodeficiency virus type 1-infected seroconverters in India. AIDS Res Hum Retroviruses 2002; 18:1175-1179.
13. Laurent C, Bourgeois A, Faye MA, Mougnutou R, Seydi M, Gueye M, et al. No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02-AG strain and patients not infected with CRF02-AG, in Western and West-Central Africa: A four-year prospective multicenter study. J Infect Dis 2002; 186:486-492.
14. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587-1590.
15. KaleebuP,Nankya IL, YirrellDL, Shafer LA, Kyosiimire-Lugemwa J, Lule DB, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45:28-33.
16. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A, et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001; 15:293-299.
17. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197:707-713.
18. Neilson JR, John GC, Carr JK, Lewis P, Kreiss JK, Jackson S, et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol 1999; 73:4393-4403.
19. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-852.
20. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002; 185:1244-1250.
21. Kiwanuka N, Robb M, Laeyendecker O, Kigozi G, Wabwire-Mangen F, Makumbi FE, et al. HIV-1 viral subtype differences in the rate of CD4R T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr 2010; 54:180-184.
22. Kuritzkes DR. HIV-1 subtype as a determinant of disease progression. J Infect Dis 2008; 197:638-639.
23. Kanki PJ, Travers KU, MBoup S, Hsieh CC, Marlink RG, Gueye-NDiaye NA, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943-946.
24. Gray CM, Williamson C, Bredell H, Puren A, Xia X, Filter R, et al. Viral dynamics and CD4R T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res Hum Retroviruses 2005; 21: 285-291.
25. Stiles T, Grant V, Mawbey N. Good clinical laboratory practice (GCLP): A quality system for laboratories that undertake the analysis of samples from clinical trials. Suffolk, United Kingdom: British Association of Research Quality Assurance (BARQA); 2003.
26. Fabiani M, Ble C, Grivel P, Lukwiya M, Declich S. 1989-1996 HIV-1 prevalence trends among different risk groups in Gulu District, North Uganda. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:514.
27. Mulenga J, Hunter E, Manigart O, Stevens G, Allen S, RZ HRG. P24 antigen screening for early detection of HIV infection in discordant heterosexual couples in Zambia. AIDS Vaccine Conference. Amsterdam, The Netherlands 2006.
28. Tang J, Cormier E, Gilmour J, Price MA, Prentice HA, Song W, et al. Human leukocyte antigen variants BM44 and BM57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes. J Virol 2011; 85:8894-8902.
29. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.MMWR RecommRep 1992; 41 (RR-17): 1-19.
30. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943-1954.
31. Karita E, Ketter N, Price MA, Kayitenkore K, Kaleebu P, Nanvubya A, et al. CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS ONE 2009; 4:e4401.
32. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-1180.
33. Essex M. Human immunodeficiency viruses in the developing world. Adv Virus Res 1999; 53:71-88.
34. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
35. Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, Lahki S, et al. Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog 2012; 8:e1003041.
36. Graham SM, Mugo P, Gichuru E, Thiongo A, Macharia M, Okuku HS, et al. Adherence to antiretroviral therapy and clinical outcomes among young adults reporting high-risk sexual behavior, including men who have sex with men, in coastal Kenya. AIDS Behav 2013; 17:1255-1265.
37. Pilcher C, Busch M, Welte A, Facente S, Kassanjee R, Keating S, et al. A novel specimen and data repository for evaluation of HIV incidence assays. 19th International AIDS Conference. Washington, DC, USA 2012.
38. Manak M, Sina S, Anekella B, Hewlett I, Sanders-Buell E, Ragupathy V, et al. Pilot studies for development of an HIV subtype panel for surveillance of global diversity. AIDS Res Hum Retroviruses 2012; 28:594-606.
39. Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, et al. Viral inhibition assay: A CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis 2010; 201:720-729.
40. Ngongo BP, Priddy F, Park H, Becker J, Bender B, Fast P, et al. Developing standards of care for HIV prevention research in developing countries-a case study of 10 research centers in Eastern and Southern Africa. AIDS Care 2012; 24:1277-1289.